• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Angiotensin converting enzyme 2 is a novel target of the ?-secretase complex

tetano

Editor, Senior Moderator
Sci Rep


. 2021 May 7;11(1):9803.
doi: 10.1038/s41598-021-89379-x.
Angiotensin converting enzyme 2 is a novel target of the ?-secretase complex


Alberto Bartolom?[SUP] 1 [/SUP], Jiani Liang[SUP] 1 [/SUP], Pengfei Wang[SUP] 2 [/SUP], David D Ho[SUP] 2 [/SUP], Utpal B Pajvani[SUP] 3 [/SUP]



Affiliations
Free article

Abstract

Angiotensin converting enzyme 2 (ACE2) is a key regulator of the renin-angiotensin system, but also the functional receptor of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Based on structural similarity with other ?-secretase (?S) targets, we hypothesized that ACE2 may be affected by ?S proteolytic activity. We found that after ectodomain shedding, ACE2 is targeted for intramembrane proteolysis by ?S, releasing a soluble ACE2 C-terminal fragment. Consistently, chemical or genetic inhibition of ?S results in the accumulation of a membrane-bound fragment of ectodomain-deficient ACE2. Although chemical inhibition of ?S does not alter SARS-CoV-2 cell entry, these data point to a novel pathway for cellular ACE2 trafficking.
 
Back
Top Bottom